Cancer Research Meeting Calendar Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Viloria-Petit, A.
Right arrow Articles by Kerbel, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Viloria-Petit, A.
Right arrow Articles by Kerbel, R. S.
[Cancer Research 61, 5090-5101, July 1, 2001]
© 2001 American Association for Cancer Research

Experimental Therapeutics

Acquired Resistance to the Antitumor Effect of Epidermal Growth Factor Receptor-blocking Antibodies in Vivo

A Role for Altered Tumor Angiogenesis1

Alicia Viloria-Petit, Tania Crombet, Serge Jothy, Daniel Hicklin, Peter Bohlen, Jean Marc Schlaeppi, Janusz Rak and Robert S. Kerbel2

Molecular and Cellular Biology Research [A. V-P., R. S. K.] and Department of Anatomic Pathology [S. J.], Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada; Clinical Immunology Division, Center of Molecular Immunology, Havana, Cuba [T. C.]; ImClone Systems, Inc., New York, New York [D. H., P. B.]; Core Technology Department, Novartis Pharmaceuticals, Novartis Limited, Basel, Switzerland [J. M. S.]; and Hamilton Civic Hospitals Research Centre, Ontario, Canada [J. R.]

Inhibitors of epidermal growth factor receptor (EGFR) signaling are among the novel drugs showing great promise for cancer treatment in the clinic. However, the possibility of acquired resistance to such drugs because of tumor cell genetic instabilities has not yet been explored. Here we report the experimental derivation and properties of such cell variants obtained from recurrent tumor xenografts of the human A431 squamous cell carcinoma, after two consecutive cycles of therapy with one of three different anti-EGFR monoclonal antibodies: mR3, hR3, or C225. Initial response to a 2-week period of treatment was generally total tumor regression and was not significantly different among the three antibody groups. However, tumors often reappeared at the site of inoculation, generally after prolonged latency periods, and most of the tumors became refractory to a second round of therapy. Cell lines established from such resistant tumors retained high EGFR expression, normal sensitivity to anti-EGFR antibody or ligand, and unaltered growth rate when compared with the parental line in vitro. In contrast, the A431 cell variants exhibited an accelerated growth rate and a significantly attenuated response to anti-EGFR antibodies in vivo relative to the parental line. Because of the reported suppressive effect of EGFR inhibitors on vascular endothelial growth factor (VEGF) expression, and the demonstrated role of VEGF in the angiogenesis and growth of A431 tumor xenografts, relative VEGF expression was examined. Five of six resistant variants expressed increased levels of VEGF, which paralleled an increase in both angiogenic potential in vitro and tumor angiogenesis in vivo. In addition, elevated expression of VEGF in variants of A431 cells obtained by gene transfection rendered the cells significantly resistant to anti-EGFR antibodies in vivo. Taken together, the results suggest that, at least in the A431 system, variants displaying acquired resistance to anti-EGFR antibodies can emerge in vivo and can do so, at least in part, by mechanisms involving the selection of tumor cell subpopulations with increased angiogenic potential.




This article has been cited by other articles:


Home page
 Ann OncolHome page
S. F. Schoppmann, D. Tamandl, L. Roberts, G. Jomrich, A. Schoppmann, R. Zwrtek, P. Dubsky, M. Gnant, R. Jakesz, and P. Birner
HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer
Ann. Onc., November 25, 2009; (2009) mdp532v1.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Medical OncologyHome page
F. Loupakis, C. Cremolini, G. Fontanini, I. Stasi, L. Salvatore, and A. Falcone
Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer
Therapeutic Advances in Medical Oncology, November 1, 2009; 1(3): 167 - 181.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
A. K. Lucio-Eterovic, Y. Piao, and J. F. de Groot
Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy
Clin. Cancer Res., July 15, 2009; 15(14): 4589 - 4599.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
J. R. TONRA, E. CORCORAN, D. S. DEEVI, P. STEINER, J. KEARNEY, H. LI, D. L. LUDWIG, Z. ZHU, L. WITTE, D. SURGULADZE, et al.
Prioritization of EGFR/IGF-IR/VEGFR2 Combination Targeted Therapies Utilizing Cancer Models
Anticancer Res, June 1, 2009; 29(6): 1999 - 2007.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. N. Naumov, M. B. Nilsson, T. Cascone, A. Briggs, O. Straume, L. A. Akslen, E. Lifshits, L. A. Byers, L. Xu, H.-k. Wu, et al.
Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
Clin. Cancer Res., May 15, 2009; 15(10): 3484 - 3494.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Al-Nedawi, B. Meehan, R. S. Kerbel, A. C. Allison, and J. Rak
Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR
PNAS, March 10, 2009; 106(10): 3794 - 3799.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Benavente, S. Huang, E. A. Armstrong, A. Chi, K.-T. Hsu, D. L. Wheeler, and P. M. Harari
Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells
Clin. Cancer Res., March 1, 2009; 15(5): 1585 - 1592.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. J.W.L. Aerts, L. Dubois, L. Perk, P. Vermaelen, G. A.M.S. van Dongen, B. G. Wouters, and P. Lambin
Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET
J. Nucl. Med., January 1, 2009; 50(1): 123 - 131.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. S. Herbst, J. V. Heymach, and S. M. Lippman
Lung Cancer
N. Engl. J. Med., September 25, 2008; 359(13): 1367 - 1380.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Bianco, R. Rosa, V. Damiano, G. Daniele, T. Gelardi, S. Garofalo, V. Tarallo, S. De Falco, D. Melisi, R. Benelli, et al.
Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
Clin. Cancer Res., August 15, 2008; 14(16): 5069 - 5080.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. K. Chang, I. Rizvi, N. Solban, and T. Hasan
In vivo Optical Molecular Imaging of Vascular Endothelial Growth Factor for Monitoring Cancer Treatment
Clin. Cancer Res., July 1, 2008; 14(13): 4146 - 4153.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
F. Ciardiello and G. Tortora
EGFR Antagonists in Cancer Treatment
N. Engl. J. Med., March 13, 2008; 358(11): 1160 - 1174.
[Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. M. Thomas, M. J. Ogagan, M. L. Freilino, S. Strychor, D. R. Walsh, W. E. Gooding, J. R. Grandis, and W. C. Zamboni
Antitumor Mechanisms of Systemically Administered Epidermal Growth Factor Receptor Antisense Oligonucleotides in Combination with Docetaxel in Squamous Cell Carcinoma of the Head and Neck
Mol. Pharmacol., March 1, 2008; 73(3): 627 - 638.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
S. Choi and J.N. Myers
Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy
Journal of Dental Research, January 1, 2008; 87(1): 14 - 32.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. B. Saltz, H.-J. Lenz, H. L. Kindler, H. S. Hochster, S. Wadler, P. M. Hoff, N. E. Kemeny, E. M. Hollywood, M. Gonen, M. Quinones, et al.
Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study
J. Clin. Oncol., October 10, 2007; 25(29): 4557 - 4561.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Baselga and J. Tabernero
Combined Antiangiogenesis and Antiepidermal Growth Factor Receptor Targeting in the Treatment of Cancer: Hold Back, We Are Not There Yet
J. Clin. Oncol., October 10, 2007; 25(29): 4516 - 4518.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Lu, X. Li, K. Liang, R. Luwor, Z. H. Siddik, G. B. Mills, J. Mendelsohn, and Z. Fan
Epidermal Growth Factor Receptor (EGFR) Ubiquitination as a Mechanism of Acquired Resistance Escaping Treatment by the Anti-EGFR Monoclonal Antibody Cetuximab
Cancer Res., September 1, 2007; 67(17): 8240 - 8247.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. Damiano, R. Caputo, S. Garofalo, R. Bianco, R. Rosa, G. Merola, T. Gelardi, L. Racioppi, G. Fontanini, S. De Placido, et al.
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts
PNAS, July 24, 2007; 104(30): 12468 - 12473.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Martin and R. Schilder
Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition
J. Clin. Oncol., July 10, 2007; 25(20): 2894 - 2901.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. A. Hudis
Trastuzumab -- Mechanism of Action and Use in Clinical Practice
N. Engl. J. Med., July 5, 2007; 357(1): 39 - 51.
[Full Text] [PDF]

Home page
 JAMAHome page
M. V. Karamouzis, J. R. Grandis, and A. Argiris
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
JAMA, July 4, 2007; 298(1): 70 - 82.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. D. Hainsworth, D. R. Spigel, C. Farley, D. S. Thompson, D. L. Shipley, and F. A. Greco
Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network
J. Clin. Oncol., May 1, 2007; 25(13): 1747 - 1752.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. G. Johns, R. M. Perera, S. C. Vernes, A. A. Vitali, D. X. Cao, W. K. Cavenee, A. M. Scott, and F. B. Furnari
The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization
Clin. Cancer Res., March 15, 2007; 13(6): 1911 - 1925.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. Tabernero
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents
Mol. Cancer Res., March 1, 2007; 5(3): 203 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Cruz, A Ocana, E Del Barco, and A Pandiella
Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer
Ann. Onc., March 1, 2007; 18(3): 421 - 430.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
W. Wu, A. Onn, T. Isobe, S. Itasaka, R. R. Langley, T. Shitani, K. Shibuya, R. Komaki, A. J. Ryan, I. J. Fidler, et al.
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade
Mol. Cancer Ther., February 1, 2007; 6(2): 471 - 483.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. I. Rini and W.K. Rathmell
Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma
Clin. Cancer Res., January 15, 2007; 13(2): 741s - 746s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. E.W. Cohen
Role of Epidermal Growth Factor Receptor Pathway-Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., June 10, 2006; 24(17): 2659 - 2665.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
A. L. Mulkeen, T. Silva, P. S. Yoo, J. C. Schmitz, E. Uchio, E. Chu, and C. Cha
Short Interfering RNA-Mediated Gene Silencing of Vascular Endothelial Growth Factor: Effects on Cellular Proliferation in Colon Cancer Cells
Arch Surg, April 1, 2006; 141(4): 367 - 374.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. H. Albert, P. Tapang, T. J. Magoc, L. J. Pease, D. R. Reuter, R.-Q. Wei, J. Li, J. Guo, P. F. Bousquet, N. S. Ghoreishi-Haack, et al.
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
Mol. Cancer Ther., April 1, 2006; 5(4): 995 - 1006.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Sosman and I. Puzanov
Molecular targets in melanoma from angiogenesis to apoptosis.
Clin. Cancer Res., April 1, 2006; 12(7): 2376s - 2383s.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Pore, Z. Jiang, A. Gupta, G. Cerniglia, G. D. Kao, and A. Maity
EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1-Independent and HIF-1-Dependent Mechanisms.
Cancer Res., March 15, 2006; 66(6): 3197 - 3204.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. du Manoir, G. Francia, S. Man, M. Mossoba, J. A. Medin, A. Viloria-Petit, D. J. Hicklin, U. Emmenegger, and R. S. Kerbel
Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts
Clin. Cancer Res., February 1, 2006; 12(3): 904 - 916.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Damiano, R. Caputo, R. Bianco, F. P. D'Armiento, A. Leonardi, S. De Placido, A. R. Bianco, S. Agrawal, F. Ciardiello, and G. Tortora
Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors
Clin. Cancer Res., January 15, 2006; 12(2): 577 - 583.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
D. Melisi, R. Caputo, V. Damiano, R. Bianco, B. M. Veneziani, A R. Bianco, S. De Placido, F. Ciardiello, and G. Tortora
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer
Endocr. Relat. Cancer, December 1, 2005; 12(4): 1051 - 1058.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. N. Rich, S. Sathornsumetee, S. T. Keir, M. W. Kieran, A. Laforme, A. Kaipainen, R. E. McLendon, M. W. Graner, B.K. A. Rasheed, L. Wang, et al.
ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors
Clin. Cancer Res., November 15, 2005; 11(22): 8145 - 8157.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. D. Hainsworth, J. A. Sosman, D. R. Spigel, D. L. Edwards, C. Baughman, and A. Greco
Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib
J. Clin. Oncol., November 1, 2005; 23(31): 7889 - 7896.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Damiano, D. Melisi, C. Bianco, D. Raben, R. Caputo, G. Fontanini, R. Bianco, A. Ryan, A. R. Bianco, S. De Placido, et al.
Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma
Clin. Cancer Res., August 1, 2005; 11(15): 5639 - 5644.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Lamszus, M. A. Brockmann, C. Eckerich, P. Bohlen, C. May, U. Mangold, R. Fillbrandt, and M. Westphal
Inhibition of Glioblastoma Angiogenesis and Invasion by Combined Treatments Directed Against Vascular Endothelial Growth Factor Receptor-2, Epidermal Growth Factor Receptor, and Vascular Endothelial-Cadherin
Clin. Cancer Res., July 1, 2005; 11(13): 4934 - 4940.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
R. Bianco, T. Troiani, G. Tortora, and F. Ciardiello
Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S159 - S171.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Baselga and C. L. Arteaga
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
J. Clin. Oncol., April 10, 2005; 23(11): 2445 - 2459.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
M. R. Raspollini, F. Castiglione, F. Garbini, A. Villanucci, G. Amunni, G. Baroni, V. Boddi, and G. L. Taddei
Correlation of Epidermal Growth Factor Receptor Expression with Tumor Microdensity Vessels and with Vascular Endothelial Growth Factor Expression in Ovarian Carcinoma
International Journal of Surgical Pathology, April 1, 2005; 13(2): 135 - 142.
[Abstract] [PDF]

Home page
 JCOHome page
B. P. Schneider and K. D. Miller
Angiogenesis of Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1782 - 1790.
[Full Text] [PDF]

Home page
 The OncologistHome page
B. I. Rini
VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma
Oncologist, March 1, 2005; 10(3): 191 - 197.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Tuccillo, M. Romano, T. Troiani, E. Martinelli, F. Morgillo, F. De Vita, R. Bianco, G. Fontanini, R. A. Bianco, G. Tortora, et al.
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor
Clin. Cancer Res., February 1, 2005; 11(3): 1268 - 1276.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. K. Goudar, Q. Shi, M. D. Hjelmeland, S. T. Keir, R. E. McLendon, C. J. Wikstrand, E. D. Reese, C. A. Conrad, P. Traxler, H. A. Lane, et al.
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
Mol. Cancer Ther., January 1, 2005; 4(1): 101 - 112.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. R. Camp, J. Summy, T. W. Bauer, W. Liu, G. E. Gallick, and L. M. Ellis
Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor
Clin. Cancer Res., January 1, 2005; 11(1): 397 - 405.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Scartozzi, I. Bearzi, R. Berardi, A. Mandolesi, G. Fabris, and S. Cascinu
Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies
J. Clin. Oncol., December 1, 2004; 22(23): 4772 - 4778.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
O. G. Yigitbasi, M. N. Younes, D. Doan, S. A. Jasser, B. A. Schiff, C. D. Bucana, B. N. Bekele, I. J. Fidler, and J. N. Myers
Tumor Cell and Endothelial Cell Therapy of Oral Cancer by Dual Tyrosine Kinase Receptor Blockade
Cancer Res., November 1, 2004; 64(21): 7977 - 7984.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Emanuel, R. H. Gruninger, A. Fuentes-Pesquera, P. J. Connolly, J. A. Seamon, S. Hazel, R. Tominovich, B. Hollister, C. Napier, M. R. D'Andrea, et al.
A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models
Mol. Pharmacol., September 1, 2004; 66(3): 635 - 647.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. E. Dancey
Epidermal Growth Factor Receptor and Epidermal Growth Factor Receptor Therapies in Renal Cell Carcinoma: Do We Need a Better Mouse Trap?
J. Clin. Oncol., August 1, 2004; 22(15): 2975 - 2977.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Raben, C. Bianco, V. Damiano, R. Bianco, D. Melisi, C. Mignogna, F. P. D'Armiento, L. Cionini, A. R. Bianco, G. Tortora, et al.
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model
Mol. Cancer Ther., August 1, 2004; 3(8): 977 - 983.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Bianco, R. Caputo, R. Caputo, V. Damiano, S. De Placido, C. Ficorella, S. Agrawal, A. R. Bianco, F. Ciardiello, and G. Tortora
Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate Cancer
Clin. Cancer Res., July 15, 2004; 10(14): 4858 - 4864.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Castillo, M. C. Etienne-Grimaldi, J. L. Fischel, P. Formento, N. Magne, and G. Milano
Pharmacological background of EGFR targeting
Ann. Onc., July 1, 2004; 15(7): 1007 - 1012.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. S. Herbst and A. B. Sandler
Non-Small Cell Lung Cancer and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab?
Oncologist, June 1, 2004; 9(suppl_1): 19 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Ciardiello, R. Bianco, R. Caputo, R. Caputo, V. Damiano, T. Troiani, D. Melisi, F. De Vita, S. De Placido, A. R. Bianco, et al.
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
Clin. Cancer Res., January 15, 2004; 10(2): 784 - 793.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. A. Sosman
Targeting of the VHL-Hypoxia-Inducible Factor-Hypoxia-Induced Gene Pathway for Renal Cell Carcinoma Therapy
J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2695 - 2702.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Filleur, A. Courtin, S. Ait-Si-Ali, J. Guglielmi, C. Merle, A. Harel-Bellan, P. Clezardin, and F. Cabon
SiRNA-mediated Inhibition of Vascular Endothelial Growth Factor Severely Limits Tumor Resistance to Antiangiogenic Thrombospondin-1 and Slows Tumor Vascularization and Growth
Cancer Res., July 15, 2003; 63(14): 3919 - 3922.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Abe, K. Terada, H. Wakimoto, R. Inoue, E. Tyminski, R. Bookstein, J. P. Basilion, and E. A. Chiocca
PTEN Decreases in Vivo Vascularization of Experimental Gliomas in Spite of Proangiogenic Stimuli
Cancer Res., May 1, 2003; 63(9): 2300 - 2305.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L. Arteaga and J. Baselga
Clinical Trial Design and End Points for Epidermal Growth Factor Receptor-targeted Therapies: Implications for Drug Development and Practice
Clin. Cancer Res., May 1, 2003; 9(5): 1579 - 1589.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L. Arteaga
Molecular Therapeutics: Is One Promiscuous Drug against Multiple Targets Better than Combinations of Molecule-specific Drugs?
Clin. Cancer Res., April 1, 2003; 9(4): 1231 - 1232.
[Full Text] [PDF]

Home page
 Ann OncolHome page
K. D. Miller, C. J. Sweeney, and G. W. Sledge
The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era
Ann. Onc., January 1, 2003; 14(1): 20 - 28.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. M.L. Ebos, J. Tran, Z. Master, D. Dumont, J. V. Melo, E. Buchdunger, and R. S. Kerbel
Imatinib Mesylate (STI-571) Reduces Bcr-Abl-Mediated Vascular Endothelial Growth Factor Secretion in Chronic Myelogenous Leukemia
Mol. Cancer Res., December 1, 2002; 1(2): 89 - 95.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. O'Reilly
Targeting Multiple Biological Pathways as a Strategy to Improve the Treatment of Cancer
Clin. Cancer Res., November 1, 2002; 8(11): 3309 - 3310.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Fukuda, K. Hirota, F. Fan, Y. D. Jung, L. M. Ellis, and G. L. Semenza
Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells
J. Biol. Chem., October 4, 2002; 277(41): 38205 - 38211.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. A. Scappaticci
Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies
J. Clin. Oncol., September 15, 2002; 20(18): 3906 - 3927.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Karashima, P. Sweeney, J. W. Slaton, S. J. Kim, D. Kedar, J. I. Izawa, Z. Fan, C. Pettaway, D. J. Hicklin, T. Shuin, et al.
Inhibition of Angiogenesis by the Antiepidermal Growth Factor Receptor Antibody ImClone C225 in Androgen-independent Prostate Cancer Growing Orthotopically in Nude Mice
Clin. Cancer Res., May 1, 2002; 8(5): 1253 - 1264.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. S. Kerbel
Clinical Trials of Antiangiogenic Drugs: Opportunities, Problems, and Assessment of Initial Results
J. Clin. Oncol., September 15, 2001; 19(90001): 45s - 51.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.